Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis
H Struyfs, E Niemantsverdriet, J Goossens… - Frontiers in …, 2015 - frontiersin.org
The goal of this study is to investigate the value of tau phosphorylated at threonine 181 (P-
tau181P) in the Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker panel for …
tau181P) in the Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker panel for …
Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression
Studies have shown that women on the Alzheimer's disease (AD) continuum have more
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
TK Karikari, A Emeršič, A Vrillon… - Alzheimer's & …, 2021 - Wiley Online Library
Introduction Phosphorylated tau (p‐tau) in cerebrospinal fluid (CSF) is an established
Alzheimer's disease (AD) biomarker. Novel immunoassays targeting N‐terminal and mid …
Alzheimer's disease (AD) biomarker. Novel immunoassays targeting N‐terminal and mid …
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective …
Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
[HTML][HTML] Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology
J Therriault, NJ Ashton, I Pola, G Triana-Baltzer… - …, 2024 - thelancet.com
Background Blood-based biomarkers of Alzheimer's disease (AD) have become
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …
Plasma p‐tau231, p‐tau181, PET biomarkers, and cognitive change in older adults
Objective The objective of this study was to evaluate novel plasma p‐tau231 and p‐tau181,
as well as Aβ40 and Aβ42 assays as indicators of tau and Aβ pathologies measured with …
as well as Aβ40 and Aβ42 assays as indicators of tau and Aβ pathologies measured with …
Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET
Y Guo, YY Huang, XN Shen, SD Chen, H Hu… - Alzheimer's research & …, 2021 - Springer
Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's
disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal …
disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal …
[HTML][HTML] Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related …
Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early
changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels …
changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels …
Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease
Cerebrospinal fluid (CSF) measures of phosphorylated-tau (P-tau) 231 and P-tau181 are
two biomarkers for the identification of tau pathology as related to Alzheimer's disease (AD) …
two biomarkers for the identification of tau pathology as related to Alzheimer's disease (AD) …
Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change
Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …